Shire Uses Foresight to Expand in Ophthalmology
This article was originally published in Scrip
Executive Summary
Shire PLC has acquired privately held Foresight Biotherapeutics for $300m, gaining FST-100, a Phase III-ready drug in development for infectious conjunctivitis and a commercial complement to Shire's lifitegrast pending at FDA.
You may also be interested in...
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Since becoming CEO of Shire in April 2013, Flemming Ornskov has overseen around $50bn in M&A deals. He steered the company through the ultimately abortive takeover by AbbVie and walked away with a break fee of $1.6bn, going on to consummate instead Shire’s $32bn acquisition of Baxalta earlier this year. He spoke to Scrip about his vision and values.
Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger
Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.